ArticleFrontiers in endocrinology2026
Arterial stenosis and electrophysiological nerve dysfunction in type 2 diabetes: clinical evidence from GEE models and transcriptomic pathway analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic peripheral neuropathy (DPN) is a common disabling complication of type 2 diabetes (T2D), yet the contribution of systemic arterial stenosis to electrophysiological nerve dysfunction remains incompletely characterized. Objective: To examine whether carotid arterial stenosis (CASD) and lower-limb arterial stenosis (LWASD) are associated with multi-nerve conduction abnormalities in T2D, and to explore supportive molecular signatures using transcriptomic analysis. Methods: In this retrospective cross-sectional study, 202 patients with T2D underwent bilateral carotid and lower-limb ultrasonography and standardized nerve conduction testing. Nerve dysfunction was quantified using 16 binary electrophysiological abnormality indicators. Generalized estimating equation (GEE) models estimated marginal associations between stenosis grades and nerve abnormality, adjusting for age and sex, with an expanded model additionally adjusting for HbA1c, LDL-cholesterol, and triglycerides to assess robustness to metabolic confounding. Patient-level abnormality burden was evaluated using a binomial model (abnormal indicators out of those assessed). Transcriptomic differential expression and pathway enrichment were performed using the public microarray dataset GSE95849 to provide supportive systemic molecular context. Results: LWASD was significantly associated with increased odds of nerve conduction abnormality and remained robust after metabolic adjustment (OR ≈ 1.5 per grade increase, p< 0.001), whereas CASD showed weaker and non-significant associations in the primary nerve-level models. Nerve-specific analyses suggested stronger signals in distal lower-limb measures consistent with a length-dependent pattern. Transcriptomic analyses highlighted enrichment of pathways related to hypoxia responses, inflammatory signaling, mitochondrial dysfunction, and neuronal maintenance. Conclusion: Lower-limb arterial stenosis is independently associated with a greater burden of electrophysiological nerve abnormalities in T2D beyond key metabolic parameters. Transcriptomic signatures support a vascular-hypoxic-inflammatory context consistent with mechanisms implicated in diabetic complications; however, causal direction cannot be inferred from cross-sectional data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.